Angiopoietin and Adverse Outcomes in Cardiac Surgery

Launched by CENTRE HOSPITALIER UNIVERSITAIRE, AMIENS · Apr 5, 2023

Keywords

ClinConnect Summary

This clinical trial, titled "Angiopoietin and Adverse Outcomes in Cardiac Surgery," is studying how certain proteins in the blood, called angiopoietins, may be related to complications that can occur after heart surgery. Specifically, the researchers are looking at how changes in the levels of angiopoietin 1 and angiopoietin 2 might reflect damage to blood vessels and help predict the risk of problems like kidney injury following cardiac surgery. The goal is to better understand these changes so doctors can improve outcomes for patients undergoing heart procedures.

To participate in this trial, you need to be an adult scheduled for cardiac surgery that involves a heart-lung machine, which helps circulate blood during the operation. Unfortunately, if you're under 18, if you're having urgent or repeat surgery, or if you have certain heart conditions, you won't be eligible to join. Participants in the study will have their blood tested before and after surgery to measure the levels of these proteins. This research could help doctors identify patients at risk for complications and lead to better care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • adult patient scheduled for cardiac surgery under cardiopulmonary bypass
• Exclusion Criteria:
• • patient less than 18 years old,
• • redo surgery,
• • urgent surgery,
• • endocarditis,
• • aortic root repair surgery
• • aortic dissection
• • heart beating surgery,
• • heart transplantation